Case | Age (years) | Gender | Underlying disease | Medication | Stage | Maximum standardized uptake value | Mean standardized uptake value | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
MRONJ | Right | Left | MRONJ | Right | Left | ||||||
1 | 74 | Female | Bone metastases from breast cancer | Denosumab | 2 | 14.0 | 11.0 | 6.61 | 5.50 | 3.43 | 2.55 |
2 | 82 | Female | Osteoporosis | Denosumab | 2 | 19.0 | 6.39 | 5.51 | 5.59 | 2.85 | 2.59 |
3 | 83 | Female | Osteoporosis | Minodronate | 2 | 16.1 | 9.90 | 8.47 | 4.87 | 2.62 | 2.54 |
4 | 85 | Female | Osteoporosis | Minodronate | 3 | 28.6 | 8.00 | 6.14 | 4.62 | 2.39 | 2.39 |
5 | 88 | Female | Osteoporosis | Minodronate | 3 | 20.0 | 6.98 | 9.38 | 6.78 | 2.04 | 3.37 |
Mean ± SD | 19.5 ± 5.6 | 8.5 ± 2.0 | 7.2 ± 1.6 | 5.5 ± 0.8 | 2.7 ± 0.5 | 2.7 ± 0.4 | |||||
P value | – | .001 | < .001 | – | < .001 | < .001 |